Allakos Inc (ALLK) - News Archive

Showing 3 of 3 results.

Allakos Inc. to be Acquired by Concentra Biosciences for $0.33 Per Share: A Pivotal Move in the Biotechnology Arena

In a significant development in the biotechnology sector, Allakos Inc. (NASDAQ: ALLK) has announced it will be acquired by Concentra Biosciences, LLC. Under the terms of the merger agreement disclosed on April 2, 2025,...

Apr 2, 2025 • Major Pharmaceutical Preparations Industry Merger and Acquisition

Allakos Reports Promising Phase 1 Results for Subcutaneous AK006 A Breakthrough in Allergy Therapy

Allakos Reports Promising Phase 1 Results for Subcutaneous AK006: A Breakthrough in Allergy Therapy In a significant advancement for the treatment of mast cell-related diseases, Allakos Inc. has announced the successful...

Oct 10, 2024 • Major Pharmaceutical Preparations Industry Clinical Study

Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Fail to Meet Primary Endpoints: Implications for Allakos' Future Development

In recent years, the field of pharmaceutical sciences has witnessed tremendous progress in the development of novel therapeutics. One such promising candidate was lirentelimab, a drug developed by Allakos Inc., aimed at...

Jan 16, 2024 • Major Pharmaceutical Preparations Industry Clinical Study